PENNINGTON BIOMEDICAL RESEARCH CENTER LSU

Statement of Cash Flows

For the Year Ended June 30, 2016

Cash flows from operating activities		
Student tuition and fees	$	-
Federal appropriations		-
ARRA receipts		-
Grants and contracts		28,989,214
Sales and services of educational departments		680,533
Hospital income		-
Auxiliary enterprise receipts		65,899
Payments for employee compensation		(24,641,510)
Payments for benefits		(9,565,069)
Payments for utilities		(1,636,442)
Payments for supplies and services		(12,683,361)
Payments for scholarships and fellowships		(2,516)
Loans to students		-
Collection of loans to students		-
Other receipts (disbursements)		(45,393)
Net cash provided (used) by operating activities		(18,838,645)
Cash flows from non-capital financing activities		
State appropriations		16,240,822
Transfer to/from other System Institutions		-
Gifts and grants for other than capital purposes		3,305,611
Private gifts for endowment purposes		54,315
TOPS receipts		-
TOPS disbursements		-
FEMA receipts		-
FEMA disbursements		-
ARRA receipts		-
Direct lending receipts		-
Direct lending disbursements		-
Federal Family Education Loan Program receipts		-
Federal Family Education Loan Program disbursements		-
Implicit loan to/from other campuses		4,490,848
Other receipts (disbursements)		5,311,742
Net cash provided (used) by noncapital financing sources		29,403,338
Cash flows from capital financing activities		
Proceeds from capital debt		-
Capital appropriations received		-
Capital grants and gifts received		-
Proceeds from sale of capital assets		-
Purchase of capital assets		(371,876)
Principal paid on capital debt and leases		-
Interest paid on capital debt and leases		-
Deposit with trustees		-
Other sources		(54,315)
Net cash provided (used) by capital financing activities		(426,191)
Cash flows from investing activities		
Proceeds from sales and maturities of investments		-
Interest received on investments		29,018
Purchase of investments		-
Net cash provided (used) by investing activities		29,018
Net increase (decrease) in cash and cash equivalents		10,167,520
Cash and cash equivalents at the beginning of the year		4,787,400
Cash and cash equivalents at the end of the year	$	14,954,920

PENNINGTON BIOMEDICAL RESEARCH CENTER LSU

Statement of Cash Flows

For the Year Ended June 30, 2016

Reconciliation of Net Operating Revenues (Expenses) to		
Net Cash Provided (used) by Operating Activities		
Operating loss	$	(21,953,598)
Adjustments to reconcile net income (loss) to net cash		
provided (used) by operating activities:		
Depreciation expense		5,738,708
Changes in assets and liabilities		
(Increase) decrease in accounts receivable, net		(90,877)
(Increase) decrease in inventories		4,700
(Increase) decrease in prepaid expenses & advances		-
(Increase) decrease in notes receivable		-
(Increase) decrease in other assets		-
Increase (decrease) in accounts payable & accrued liabilities		(29,497)
Increase (decrease) in unearned revenues		(2,528,776)
Increase (decrease) in amounts held in custody for others		-
Increase (decrease) in compensated absences		128,986
Increase (decrease) in OPEB payable		2,184,780
Increase (decrease) in NPL and associated deferrals		(2,126,403)
Increase (decrease) in other liabilities		(166,668)
Net cash provided (used) by operating activities:		(18,838,645)
Noncash Investing, Noncapital Financing, and Capital &		
Related Financing Transactions		
Capital appropriations		525,044
Capital gifts and grants		30,473,152
Net non-cash transactions		30,998,196
Reconciliation of Cash & Cash Equivalents to the SNP		
Cash and cash equivalents classified as current assets		9,515,877
Cash and cash equivalents classified as noncurrent assets		5,439,043
	$	14,954,920